A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab In Patients With Recurrent Or Metastatic Head and Neck Cancer.

Trial Profile

A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab In Patients With Recurrent Or Metastatic Head and Neck Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Fluorouracil
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2015 Safety analysis results ( n=357) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 24 Aug 2012 Planned end date changed from 1 Dec 2017 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top